二甲双胍联合黄连素治疗肥胖型多囊卵巢综合征的临床分析被引量：2

下载PDF

导出

摘要目的观察黄连素与二甲双胍联合应用治疗肥胖型多囊卵巢综合征(pcos)的临床疗效。方法采用随机数字表法,将2012年5月—2015年6月山东大学历城区妇幼保健所妇产科门诊收治的84例肥胖型多囊卵巢综合征患者分为常规组和联合组,每组各42例,常规组给予二甲双胍治疗,联合组在常规组的基础上给予黄连素治疗,所有患者均治疗3个月。结果治疗后联合组体重指数(BIM)、腰臀比(WHR)明显低于常规组,差异有统计学意义(P<0.05);两组患者治疗前卵泡刺激素(FSH)、黄体生成激素(LH)、LH/FSH比值、稳态胰岛素评估指数(HOMA-IR)和睾酮(T)比较差异无统计学意义(P>0.05)。经过3个月治疗后,联合组患者LH/FSH、LH、HOMA-IR和T均显著低于常规组,差异有统计学意义(P<0.05);治疗前两组患者排卵率较低,治疗后联合组患者排卵率明显高于常规组,差异有统计学意义(P<0.05)。结论采用二甲双胍联合黄连素治疗肥胖型多囊卵巢综合征,可以有效地改善患者肥胖体征,降低患者激素水平,提升患者排卵率。

作者王萍王虎王玉洁

机构地区山东大学历城区妇幼保健所山东大学附属山东大学中心医院

出处《中国初级卫生保健》 2016年第10期77-78,82,共3页 Chinese Primary Health Care

关键词二甲双胍肥胖型多囊卵巢综合征黄连素联合应用疗效

分类号 R711.75 [医药卫生—妇产科学]

引文网络
相关文献

参考文献6

1陈薪,尹敏娜,叶德盛,何于夏,陈士岭.血清与卵泡液抗苗勒氏管激素对多囊卵巢综合症患者体外受精-胚胎移植临床结果的预测价值[J].南方医科大学学报,2013,33(4):546-549. 被引量：37
2刘会芹,申文娟,张景莲.中西医结合治疗多囊卵巢综合症致月经失调的临床疗效观察[J].河北医学,2013,19(9):1423-1425. 被引量：26
3代晶芳,李晓林,孙宝治.多囊卵巢综合征易感基因多态性的研究进展[J].山东医药,2013,53(34):98-101. 被引量：18
4黄浓香,黄姣莲.克罗米芬联合人绒毛膜促性腺激素治疗PCOS疗效观察[J].中华全科医学,2013,11(6):905-905. 被引量：26
5向大清,陈玲,曾林.氯米芬与他莫昔芬治疗多囊卵巢综合症不孕患者临床疗效对比观察[J].河北医学,2016,22(2):284-287. 被引量：29
6汪凌霄,孔园珍,任延巍,沈梅.黄连素联合二甲双胍治疗胰岛素抵抗多囊卵巢综合征的临床研究[J].浙江中医药大学学报,2011,35(5):713-715. 被引量：7

二级参考文献70

1Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti- mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest[J]. J Clin Endocrinol Metab, 2003, 88(12): 5957-62.
2Choi MH, Yoo JH, Kim HO, et al. Serum anti-Mtillerian hormone levels as a predictor of the ovarian response and WF outcomes[J]. Clin Exp Reprod Med, 2011, 38(3): 153-8.
3Honnma H, Baba T, Sasaki M, et al. Serum anti-Mullerian hormone levels affect the rate of ongoing pregnancy after in vitro fertilization [J]. Reprod Sci, 2013, 20(1): 51-9.
4Weghofer A, Kim A, Barad DH, et al. Follicle stimulating hormone and anti-Miillerian hormone per oocyte in predicting in vitro fertilization pregnancy in high responders: a cohort study[J]. PLoS One, 2012, 7(4): e34290.
5Sahmay S, Demirayak G, Guralp O, et al. Serum anti-miallerian hormone, follicle stimulating hormone and antral follicle count measurement cannot predict pregnancy rates in IVF/ICSI cycles[J]. J Assist Reprod Genet, 2012, 29(7): 589-95.
6Silverberg K, Burger N, Hansard L, et al. Both AMH and day 3 FSH levels predict IVF stimulation outcome regardless of patient age; day 3 estradiol levels are not predictive [abstract] [J]. Fertil Steril. 2012.98(3): S273.
7Hazout A, Bouchard P, Seifer DB, et al. Serum antimtillerian hormone/mtillerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol [J]. Fertil Steril. 2004. 82(5): 1323-9.
8Silberstein T, Maclaughlin DT, Shai I, et al. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology [J]. Hum Reprod, 2006, 21(1): 159-63.
9Lehmann L, Del PM, Saumet J, et al. Anti-Miillerian hormone: a reliable biomarker of oocytes quality in stimulated in vitro fertilization [abstract] [J]. Fertil Steril, 2012, 98(3): S 116.
10Mashiach R, Amit A, Hasson J, et al. Follicular fluid levels of anti-Mullerian hormone as a predictor of oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome[J]. Fertil Steril, 2010, 93(7): 2299-302.